논문번호 | 236 | ||
논문제목(영문) | Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial | ||
국내외구분 | 국외 | SCI여부 | SCI |
연구책임자역할 | 공저자 | ||
주저자명 | Chee Hae Kim | ||
교신저자명 | Chee Hae Kim | ||
공동저자명 | Kyung Woo Park,Jeehoon Kang,Byoung-Eun Park,Kwang Soo Cha,Myung-Ho Jeong, et at. HOST–ASSURE Investigators | ||
게제년월일 | 2019-05-31 | ||
ISSN | 1346-9843. | ||
Impact Factor | 2.54 | ||
학술지명 | Circulation Journal | ||
서지사항 | 0집 / 83권 / 7호, 페이지(1489 - 1497) | ||
요약초록문 (Abstract) 입력 |
Background: There are limited data on the long-term outcome of platinum chromium-based everolimus-eluting stents (PtCr-EES) vs. cobalt chromium-based zotarolimus-eluting stents (CoCr-ZES).Methods and Results:A total of 3,755 patients undergoing percutaneous coronary intervention (PCI) were randomized 2:1 to PtCr-EES or CoCr-ZES, and 96.0% of patients completed the 3-year clinical follow-up. The primary outcome was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR). At 3 years, TLF occurred in 5.3% and in 5.4% of the PtCr-EES and CoCr-ZES groups, respectively (hazard ratio 0.978; 95% confidence interval 0.730-1.310, P=0.919). There were no significant differences in the individual components of TLF. Routine angiographic follow-up was performed in 38.9% of the total patients. In a landmark analysis of the subgroup that had follow-up angiography, the clinically-driven TLR rate of CoCr-ZES was significantly higher than PtCr-EES group during the angiography follow-up period (P=0.009). Overall definite and probable stent thrombosis rates were very low in both groups (0.5% vs. 0.6%, P=0.677). Conclusions: PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population. |
||
파일 |
.236.pdf (46.2K) DATE : 2021-06-07 22:50:41 |
전라남도 장성군 남면 삼태리 산 109 나노바이오연구원 3층 306호 TEL : 061-392-6243 Fax: 061-392-6243
Copyright ⓒ 2014 Korea Cardiovascular Stent Research Institute. All right Reserved